Neuromodulation Devices Market To Reach $13.93 Billion By 2033

December 2025 | Report Format: Electronic (PDF)

Neuromodulation Devices Market Growth & Trends

The global neuromodulation devices market size is expected to reach USD 13.93 billion by 2033, registering a CAGR of 10.35% from 2026 to 2033, according to a new report by Grand View Research, Inc. The market's growth can be attributed to factors such as rising prevalence of neurological disorders, rising government support to R&D and development of advanced solutions with increased range of applications.

Significant funding from government and private agencies plays a crucial role in advancing the understanding of neurological disorders and improving treatment options. By allocating resources to research initiatives, governments actively facilitate groundbreaking discoveries, encourage technological innovations, and promote the development of more effective neuromodulation technologies. For instance, in August 2024, the Parkinson's Foundation announced an investment of nearly USD 3 million in 33 research grants aimed at advancing the understanding and treatment of Parkinson's disease (PD). This funding will support innovative research projects focusing on various aspects of PD, including its causes, progression, and potential therapies. The grants are part of the Foundation's commitment to fostering scientific advancements that can lead to improved patient outcomes. This financial backing is vital for shaping the treatment landscape for neurological disorders and driving positive changes in patient care.

Furthermore, the increasing accessibility of these advanced devices to patients and healthcare professionals has further increased their adoption. Expanding reimbursement is improving patient access to these advanced therapies. In recent years, healthcare systems have increasingly acknowledged the effectiveness of neuromodulation devices in managing chronic pain, neurological disorders, and various other medical conditions, which has led many healthcare payers to include these devices in their coverage policies. For instance, in February 2024, Nerivio Remote Electrical Neuromodulation (REN) wearable by Theranica became the first non-pharmacological migraine treatment to get commercial coverage in the U.S. from Highmark Inc. The wearable offers acute and preventive treatment options, demonstrating significant clinical benefits in reducing migraine symptoms. Thus, the growing acceptance of neuromodulation therapies among payers is driving market growth.

key Request a free sample copy or view report summary: Neuromodulation Devices Market Report

Neuromodulation Devices Market Report Highlights

By product, the spinal cord stimulators segment led the market with the largest revenue share in 2025. The deep brain stimulators segment is anticipated to grow at the fastest CAGR in the neuromodulation devices market.
By application, the parkinson’s disease segment led the market with the largest revenue share in 2025. The chronic pain segment is expected to grow at the fastest CAGR in the neuromodulation devices market.
By end-use, the hospitals & ambulatory surgery centers (ASC) segment led the market with the largest revenue share in 2025 and are expected to witness the fastest growth over the forecast period.
North America dominated the neuromodulation devices market with the largest revenue share of 43.37% in 2025. The neuromodulation devices market in the U.S. accounted for the largest market revenue share in North America in 2025.